We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Three Late-Stage Trials Support Novartis COPD Drug’s Efficacy
Three Late-Stage Trials Support Novartis COPD Drug’s Efficacy
April 6, 2012
Novartis’ inhaled once-daily drug for chronic obstructive pulmonary disease (COPD), QVA149, met its primary endpoints in its first three Phase III trials, the Swiss-owned drugmaker says.